TUBA1A

Tubulin alpha-1A chain · Q71U36 · TUBA1A on Sugi Atlas →

132,449 patent compounds predicted against TUBA1A, 83,696 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Curacin A Curacin A (SCHEMBL61304) 1.00 20/20
Vintriptol Vintriptol (SCHEMBL93959) 1.00 15/20
Vindesine Vindesine (SCHEMBL4420) 0.85 13/20
Vindesine Vindesine (SCHEMBL4421) 0.85 13/20
Vindesine Vindesine (SCHEMBL4285) 0.85 12/20
SCHEMBL147173 SCHEMBL147173 0.50 12/20
SCHEMBL147174 SCHEMBL147174 0.50 12/20
Combretastatin Combretastatin (SCHEMBL19955) 1.00 9/20
Combretastatin Combretastatin (SCHEMBL19956) 1.00 9/20
SCHEMBL118593 SCHEMBL118593 0.69 9/20
Centaureidin Centaureidin (SCHEMBL9953) 1.00 8/20
Thiocolchicine Thiocolchicine (SCHEMBL43160) 1.00 8/20
Thiocolchicine Thiocolchicine (SCHEMBL43161) 1.00 8/20
SCHEMBL68067 SCHEMBL68067 0.62 8/20
Fosbretabulin Fosbretabulin (SCHEMBL66079) 0.61 8/20
Vinorelbine Vinorelbine (SCHEMBL4765) 1.00 7/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18945) 1.00 7/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18946) 1.00 7/20
Levofloxacin Anhydrous Levofloxacin Anhydrous (SCHEMBL15397) 0.98 7/20
Ofloxacin Ofloxacin (SCHEMBL24373) 0.98 7/20

Clinical trials — most relevant to TUBA1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer PHASE3COMPLETED
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer PHASE3SUSPENDED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients. PHASE3COMPLETED
Vit D and Peripheral Neuropathy in Taxane Naive Patients PHASE2UNKNOWN
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations PHASE2COMPLETED
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer PHASE2COMPLETED
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer PHASE2UNKNOWN
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy PHASE2COMPLETED
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer PHASE2COMPLETED
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer PHASE1/PHASE2NOT_YET_RECRUITING
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Exploratory Evaluation of [11C]MPC6827 EARLY_PHASE1COMPLETED
Effect of Low Dose of Colchicine on Platelet Reactivity nanCOMPLETED
Diagnostic of Chemotherapy Induced Neuropathy in Children nanCOMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Importance of the Microtubule Cytoskeleton in Oocyte Competence nanCOMPLETED
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients nanCOMPLETED
Genetic Study of Patients With Primary Ciliary Dyskinesia nanCOMPLETED
Diagnosis of Primary Ciliary Dyskinesia nanCOMPLETED
Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy nanUNKNOWN
Mapping Disease Pathways for Biliary Atresia nanRECRUITING
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TUBA1A binder may also engage these)

ProteinNameSimilarity
P02552 1.000 P02552 →
P68369 1.000 P68369 →
A5A6J1 1.000 A5A6J1 →
TUBA4A Tubulin alpha-4A chain 1.000 landscape →
P68370 1.000 P68370 →
P68360 1.000 P68360 →
Q52PV9 1.000 Q52PV9 →
Q2HJ86 1.000 Q2HJ86 →
Q2HJB8 1.000 Q2HJB8 →
P68361 1.000 P68361 →
P34690 1.000 P34690 →
Q5R1W4 1.000 Q5R1W4 →
P18288 1.000 P18288 →
Q94572 1.000 Q94572 →
Q32KN8 1.000 Q32KN8 →
Q6AYZ1 1.000 Q6AYZ1 →
P68373 1.000 P68373 →
P68368 1.000 P68368 →
P68367 1.000 P68367 →
Q6AY56 1.000 Q6AY56 →
Q68FR8 1.000 Q68FR8 →
Q06331 1.000 Q06331 →
Q5XIF6 1.000 Q5XIF6 →
TUBA8 Tubulin alpha-8 chain 1.000 landscape →
P36220 1.000 P36220 →
P28287 1.000 P28287 →
Q28IX8 1.000 Q28IX8 →
B9DHQ0 1.000 B9DHQ0 →
P30436 1.000 P30436 →
Q8T6A5 1.000 Q8T6A5 →